Invasive cervical cancer risk among HIV-infected women: A North American multicohort collaboration prospective study

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 4, 2013, Pages 405-413

  Abraham, Alison G ^a   D'Souza, Gypsyamber ^a   Jing, Yuezhou ^a   Gange, Stephen J ^a   Sterling, Timothy R ^c   Silverberg, Michael J ^d   Saag, Michael S ^e   Rourke, Sean B ^f   Rachlis, Anita ^f   Napravnik, Sonia ^g   Moore, Richard D ^h   Klein, Marina B ⁱ   Kitahata, Mari M ^j   Kirk, Gregory D ^a   Hogg, Robert S ^k   Hessol, Nancy A ^l   Goedert, James J ^m   Gill, M John ⁿ   Gebo, Kelly A ^h   Eron, Joseph J ^g   Engels, Eric A ^m   Dubrow, Robert ^o   Crane, Heidi M ^j   Brooks, John T ^p   Bosch, Ronald J ^q   Strickler, Howard D ^b   more..

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DIVISION OF RESEARCH   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

^j UNIVERSITY OF WASHINGTON   (United States)

^k SIMON FRASER UNIVERSITY   (Canada)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o YALE UNIVERSITY   (United States)

^p CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^q HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

HIV infection; Human papillomavirus; Immunosuppression; Invasive cervical cancer

Indexed keywords

ABACAVIR; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TENOFOVIR;

CANCER GRADING; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS LOAD;

EID: 85028107223     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828177d7     Document Type: Review

References (37)

1. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency viruspositive women. J Natl Cancer Inst. 2005;97:577-586.
2. Ahdieh L, Munoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol. 2000;151:1148-1157.
3. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and typespecific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis. 2001;184:682-690.
4. Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1349.
5. Massad LS, Ahdieh L, Benning L, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2001;27:432-442.
6. Six C, Heard I, Bergeron C, et al. Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. AIDS. 1998;12: 1047-1056.
7. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA. 2005;293:1471-1476.
8. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency viruspositive women. J Natl Cancer Inst. 2005;97:577-586.
9. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA. 2005;293:1471-1476.
10. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst. 2003;95:1062-1071.
11. Strickler HD. Does HIV/AIDS have a biological impact on the risk of human papillomavirus-related cancers? J Natl Cancer Inst. 2009;101: 1103-1105.
12. Castro KG, Ward JW, Slutsker L, et al. Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Atlanta, GA: Centers for Disease Control and Prevention; 1993. Morbidity and Mortality Weekly Report June 17, 2012.
13. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962-972.
14. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus- associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101:1120-1130.
15. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97:425-432.
16. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-736.
17. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152-1159.
18. Gange SJ, Kitahata MM, Saag MS, et al. Cohort profile: the North American AIDS cohort Collaboration on research and Design (NAACCORD). Int J Epidemiol. 2007;36:294-301.
19. Franco EL, Rohan TE. Assessing Epidemiologic Relations and the Role of Measurement Error. Cancer Precursors: Epidemiology, Detection and Prevention. New York: Springer-Verlag; 2002.
20. Surveillance Epidemiology and End Result (SEER) Program, SEER*Stat Database. Age-Adjusted SEER Incidence Rates, Cancer of the Cervix Uteri (Invasive)-SEER 13 Regs Research Data, Nov 2010 Sub (1992- 2008) With Katrina/Rita Adjustment, Linked to County Attributes, Total US, 1969-2009 Counties National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011 based on November 2010 submission. 2010. Available at: http://www.seer.cancer.gov. Accessed March 31, 2012.
21. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153: 452-460.
22. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207.
23. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society Guideline for the early detection of cervical neoplasia and cancer. J Low Genit Tract Dis. 2003;7:67-86.
24. U.S. Preventive Services Task Force. Screening for Cervical Cancer. 2012. Rockville, MD: U.S. Preventive Services Task Force. Available at: http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm. Accessed March 1, 2012.
25. National Cancer Institute. PDQ® Cervical Cancer Screening. Bethesda, MD: National Cancer Institute. Available at: http://cancer.gov/cancertopics/pdq/ screening/cervical/HealthProfessional. Accessed February 5, 2012. 2012.
26. Eggleston KS, Coker AL, Das IP, et al. Understanding barriers for adherence to follow-up care for abnormal pap tests. J Womens Health (Larchmt). 2007;16:311-330.
27. Battaglia TA, Santana MC, Bak S, et al. Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers. Cancer. 2010;116:913-921.
28. Kuo TM, Benard VB, Berkman ND, et al. Timing of colposcopy after cervical cytologic abnormalities. Obstet Gynecol. 2010;115:629-636.
29. Benard VB, Lawson HW, Eheman CR, et al. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005;105:1323-1328.
30. Coker AL, Eggleston KS, Meyer TE, et al. What predicts adherence to follow-up recommendations for abnormal Pap tests among older women? Gynecol Oncol. 2007;105:74-80.
31. McKee MD, Lurio J, Marantz P, et al. Barriers to follow-up of abnormal Papanicolaou smears in an urban community health center. Arch Fam Med. 1999;8:129-134.
32. Melnikow J, Chan BK, Stewart GK. Do follow-up recommendations for abnormal Papanicolaou smears influence patient adherence? Arch Fam Med. 1999;8:510-514.
33. Peterson NB, Han J, Freund KM. Inadequate follow-up for abnormal Pap smears in an urban population. J Natl Med Assoc. 2003;95:825-832.
34. Cejtin HE, Komaroff E, Massad LS, et al. Adherence to colposcopy among women with HIV infection. J Acquir ImmuneDefic Syndr. 1999;22:247-252.
35. Baranoski AS, Stier EA. Factors associated with time to colposcopy after abnormal pap testing in HIV-infected women. J Womens Health (Larchmt). 2012;21:418-424.
36. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis. 2010;201:681-690.
37. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis. 2007;11:90-97.